This document discusses cancer vaccines and their different types. It notes that therapeutic cancer vaccines are administered to cancer patients to strengthen their immune response against cancer cells. The document outlines several types of cancer vaccines including tumor cell vaccines, dendritic cell vaccines, and protein/peptide vaccines. It provides details on specific examples of vaccines for different cancer types as well as strategies for improving vaccine design and potency, such as modifying dendritic cells or combining antigens with immune adjuvants.
1. Cancer vaccines
Ihab Muhammad Mahmoud
Medical Research Institute āAlexandria
Tumor Immunology
11/04/2018
18/04/2018
2. Cancer vaccines
Unlike prophylactic vaccines that are generally
administered to healthy individuals, therapeutic
cancer vaccines are administered to cancer
patients.
3. Cancer vaccines
ā¢ Cancer vaccines are designed to eradicates
cancer cells through strengthening patientās
own immune responses.
ā¢ Cancer vaccines inhibit further growth of
advanced cancers and/or relapsed tumors that
are refractory to conventional therapies
(surgery, radiation and chemotherapy).
4. Cancer vaccines
ā¢ Coleyās toxin (mixed
bacterial vaccine):
injected intratumoral to
stimulate the immune
system for improving a
cancer patientās
condition.
ā¢ Coleyās principle was
correct and the vaccine
was effective.
5. Cancer vaccines
ā¢ BCG is one similar example as the Coley's
Toxin, is still being used intravesically to treat
superficial bladder cancer.
ā¢ FDA has approved two prophylactic vaccines
for:
ā Hepatitis B virus that can cause liver cancer (HCC).
ā Human papillomavirus accounting for 70% of
cervical cancers.
ā¢ Cancer vaccines have achieved clinical proof-
of-concept of therapeutic cancer vaccines.
6. Cancer vaccines
ā¢ Based on their content/format, cancer
vaccines may be classified into:
1. Cell vaccines (tumor).
2. Cell vaccines (immune cells).
3. Protein/peptide vaccines.
4. Genetic (DNA, RNA and viral).
8. (1) Tumor cell vaccines
1- Autologous tumor cell vaccines
ā¢ Prepared using patient-
derived tumor cells:
1. Tumor cells are typically
irradiated.
2. Combined with an
immunostimulatory
adjuvant (eg. BCG).
3. Administered to the
individual from whom
the tumor cells were
isolated.
9. (1) Tumor cell vaccines
1- Autologous tumor cell vaccines
ā¢ Autologous tumor cell vaccines has been
tested in various cancers:
ā Lung cancer.
ā Colorectal cancer.
ā Melanoma.
ā Renal cell cancer.
10. (1) Tumor cell vaccines
1- Autologous tumor cell vaccines
ā¢ Advantage of the whole tumor cell vaccines :
ā potential to present the entire spectrum of tumor
associated antigens to the patientās immune
system.
ā¢ Disadvantage and limitation:
ā Preparation requires sufficient tumor specimen,
which limits this technology to only certain tumor
types or stage.
11. (1) Tumor cell vaccines
1- Autologous tumor cell vaccines
Autologous tumor cells may be modified to
confer higher immunostimulatory
characteristics.
ā¢ Immunization with tumor cells engineered to
express IL-12:
ā¢ Promoting Th1 immunity.
ā¢ Higher INF-Ī³ production.
ā¢ Increased activation of CTL and NK cells.
ā¢ Tumor cell transduced with costimulatory
molecule B7-1 showed antitumor effect.
12. (1) Tumor cell vaccines
1- Autologous tumor cell vaccines
ā¢ GM-CSF-transduced autologous tumor cell vaccines(GVAX):
o Recruits DCs.
o Presentation of TAs and priming CD8+ T cells.
o Stimulates maturation of DCs by up-regulation of B7-1
expression.
13.
14. (1) Tumor cell vaccines
1- Autologous tumor cell vaccines
ā¢ GVAX combination with CTLA-4 inhibitor, alter the
balance of T eff and T reg.
ā¢ Combination blockade of PD-1 and CTLA-4 with FVAX:
ā Pd-1 interaction with PD-L1/L2 or B7-1 inhibit T cell
activation and cytokine production.
ā Blockade of the negative costimulatory pathways favors
the expansion of tumorāspecific T cells and maintenance
of their effector functions
ā Resulting in shifting the immunosuppressive tumor
microenvironment to inflammatory/ immunostimulatory
state.
ā¢ GVAX was formulated with LPS, a TLR4 agonist:
ā Enhanced antitumor effect correlated with increased
tumor infiltration by activated DCs, CD8+ and CD4+ T
cells.
15.
16.
17. (1) Tumor cell vaccines
2- Allogenic tumor cell vaccines
ā¢ Contain two or three established human tumor
cell lines.
ā¢ Overcome the limitations of autologaous tumor
cell vaccines.
ā Limitless sources of TAs
ā Standardized.
ā Large-scale vaccine production.
ā Reliable analysis of clinical outcomes.
ā Easy manipulation for expression of
immunostimulatory molecules.
ā Cost- effectiveness.
18. (1) Tumor cell vaccines
2- Allogenic tumor cell vaccines
ā¢ CanvaxinĀ® vaccine is an allogenic whole-cell
vaccine consisting of three melanoma lines
combined with BCG as an adjuvant.
ā¢ An allogenic tumor cell vaccine
(belagenpumatucel-L) consisting of four non-
small cell lung cancer cell lines engineered to
secret antisense oligonucleotide to
immunosuppressive cytokine TGF-B.
19.
20.
21. (2) DC vaccines
ā¢ DCs are the most professional APCs.
ā¢ DCs act as sentinels at peripheral tissues.
ā¢ DCs uptake, process, and present pathogen- or
host-derived antigenic peptides to naiive T
lymphocytes at lymphoid organs.
ā¢ DCs bridging innate and adaptive immunity.
ā¢ ļØ Cancer immunotherapeutic strategies
target DCs directly or indirectly for the
induction of antigen-specific immune
responses
22.
23. (2) DC vaccines
ā¢ DC maturation signals are critical for
ā avoiding the induction of T cell tolerance
ā or augmentation of effective antitumor immunity.
ā¢ Three interactive signals are required for
functional activation of DCs ā innate and
adaptive immunity against cancer:
1. Loading of MHC-peptide to DCs for T cell priming.
2. Costimulatory molecules such as CD40, CD80 and
CD86.
3. Production of cytokines capable to polarize a Th1/Tc
immune response.
24.
25.
26. (2) DC vaccines
1- Ex vivo generated DCs as cancer vaccines
ā¢ Preparation of DC vaccines:
ā Loading tumor associated antigen to patientās
autologous DCs (treated with adjuvants).
ā These antigen-loaded, ex vivo matured DCs are
administered back into patients to induce antitumor
immunity.
ā¢ Antigens utilized:
ā Tumor-derived proteins or peptides.
ā Whole tumor cells.
ā DNA/RNA/Virus.
27.
28.
29. (2) DC vaccines
1- Ex vivo generated DCs as cancer vaccines
ā¢ DC vaccines have been tested in clinical trials for
the treatment of:
ā Prostate cancer.
ā Melanoma.
ā Renal cell carcinoma.
ā¢ Limitation: The autologous vaccine regimen
consists of :-
1. leukaphareses to isolate PBMCs from the patients
2. cell culture processing
ā These limits the number of vaccinations.
30. (2) DC vaccines
1- Ex vivo generated DCs as cancer vaccines
ā¢ Sipuleucel-T (ProvengeĀ®)FDA approved for
treatment of metastatic castrate-resistant
prostate cancer.
ā¢ This vaccine consists of APCs contain prostatic
acid phosphatase (PAP, a prostate antigen)
fused with GM-CSF.
ā¢ Sipuleucel-T as the first therapeutic cancer
vaccine.
31.
32. (2) DC vaccines
1- Ex vivo generated DCs as cancer vaccines
ā¢ Autologous DCs are
isolated from a patientās
blood and cultured with
a fusion protein
consisting of the
prostate cancer specific
antigen PAP and the
APC-activating cytokine
GM-CSF (PAP/GM-CSF).
33. (2) DC vaccines
1- Ex vivo generated DCs as cancer vaccines
ā¢ DCs take up and process
these antigens, after
which they are
reinfused into the
patient in order to
stimulate a T-cell
response against PAP
expressed on tumor
cells in the prostate.
34.
35. (2) DC vaccines
2- Modification of DC to improve vaccine
potency
ā¢ Despite the clinical success of APC-based
prostate cancer vaccines, the modest
antitumor efficacy of Sipuleucel-T emphasize
the need for improvement and optimization of
this approach.
36.
37. (2) DC vaccines
2- Modification of DC to improve vaccine
potency
ā¢ T cell activation is controlled by co-stimulatory
molecules expressed on DCs.
ā¢ Modification in the expression levels of
activating or inhibitory molecules could
enhance the DC vaccine potency.
ā¢ CD40 stimulation on DCs (by activated CD4+
T cells) is required for DC licensing and cross-
priming of CD8+ T cell responses.
38. (2) DC vaccines
2- Modification of DC to improve vaccine
potency
1. CD40L overexpression in mouse via
ā virus transduction..
ā mRNA electroporation led to :
ā ļØelevated expression of B-7 molecules
ā ļØenhanced IL-12p70
ā ļØTh1 antitumor immunity.
39. (2) DC vaccines
2- Modification of DC to improve vaccine
potency
2. Modulation of:
ā Stimulatory molecules, such as ; CD70, 4-1BBl and
OX40L
ā Or pro-inflammatory factors, such as ; IL-12p70,
IL-2, IL-18, CCR7 and CXCL10
ā ļØEnhance DC functionā maturation, activation,
migration and capacity to stimulate antigen-
specific Th1 and CTL responses.
40. (2) DC vaccines
2- Modification of DC to improve vaccine
potency
3. A20 (ubiquitin-editing enzyme, negatively
regulates both TLRs and TNF receptors
signaling-induced maturation of DCs) silencing
in human DCs :
āFacilitates the development of INF-Ī³ producing
Th1 cells and antigen-specific CD8+ T cells.
41.
42. (2) DC vaccines
2- Modification of DC to improve vaccine
potency
4. SRA/CD204 (attenuates TLR4-engaged NF-
kB-TRAF6 signaling pathways in DCs and
downregulates the immunogenicity of DCs
and CTL-mediated antitumor immunity)
absence or silencing :
āenhances the immunostimulating, antigen-
presenting functions of DCs.
43.
44. (3) Protein/peptide-based cancer
vaccines
ā¢ Limitations of autologous cancer vaccines
(whole tumor cell & DCās):
ā Availability of patientās samples.
ā Complex procedure of preparing individualized
vaccines.
47. (3) Protein/peptide-based cancer vaccines
1-Tumor-associated antigens as therapeutic
targets.
ā¢ Recombinant vaccines, which are based on
peptides from defined
ā tumor-associated antigens(TAA),
ā tumor specific antigens (TSA),
ā or other tumor antigens
ā¢ administered together with adjuvant or an
immune modulator.
48. (3) Protein/peptide-based cancer vaccines
1-Tumor-associated antigens as therapeutic
targets.
ā¢ MAGE-1 gene was the first reported to encode
a human tumor antigen recognized by T-cells.
49. (3) Protein/peptide-based cancer vaccines
1-Tumor-associated antigens as therapeutic
targets.
ā¢ Antigens may be classified into several majour
categories:
1. Cancer testis antigens (MAGE, BAGE,ā¦)
2. Tissue differentiation antigens : of normal
tissue origin shared by both normal and
tumors:
ā Melanoma: (gp100, Melan-A, tyrosinase,..).
ā Prostate cancer: (PSA,PAP).
ā Breast carcinomas: (mammoglobin-A).
50. (3) Protein/peptide-based cancer vaccines
1-Tumor-associated antigens as therapeutic
targets
3. Tumor differentiation-associated antigens:
ā CEA.
ā HER2/Neu
ā Tumor suppressor gene : (p53).
ā Anti-appoptotic protiens.
4. Tumor specific antigens are often mutated
oncogens (Ras,..)
ā Adv. more effective.
51. (3) Protein/peptide-based cancer vaccines
1-Tumor-associated antigens as therapeutic
targets
ā¢ Advantage:
ā Protein/peptide-based cancer vaccines
are most cost effective than autologous or
individualized vaccines.
ā¢ Disadvantage:
ā Target only one epitope or few epitopes of TAA for
induction of both antigen-specific CTLs and
antigen specific CD4+ helper t-cells.
52. (3) Protein/peptide-based cancer vaccines
2-Immunostimulatory adjuvants for
protein/peptide-based vaccines.
ā¢ TAAs are poorly immunogenic in nature.
ā¢ Immunostimulatory adjuvant is essential for
generation of an effective immune response
eg. Aluminum salts (alum).
ā¢ Radical altered theories as how adjuvants
promote adaptive immunity.
ā¢ Adaptive immune responses are preceded by,
and dependent on, innate immunity receptors
(PAMPs eg. TLRs).
53. (3) Protein/peptide-based cancer vaccines
2-Immunostimulatory adjuvants for
protein/peptide-based vaccines.
ā¢ TLR-mediated activation of APCs (eg. DCs) is a
crucial step.
ā¢ Experimental vaccines incorporate PAMPs
(molecularly and functionally defined
molecules as adjuvant) as a part of
therapeutic immunizations against cancer.
54. (3) Protein/peptide-based cancer vaccines
2-Immunostimulatory adjuvants for
protein/peptide-based vaccines.
ā¢ TLR agonists have strong potential in
promoting the immunogenicity of weakly
immnunogenic TAAs.
ā Several protein/peptide-based cancer vaccines
combined with TLR agonists being tested in clinical
trials.
ā Eg.BCG (TLR agonist) used in the treatment of
bladder carcinoma, show to activate TLR2 and
TLR4.
55. (3) Protein/peptide-based cancer vaccines
2-Immunostimulatory adjuvants for
protein/peptide-based vaccines.
ā¢ As PAMPs sense exogenous signals, DAMPS
(damaged-associated molecular patterns) are
intrinsic (endogenous) alarmins eg. HSPs.
ā¢ Stress/Heat shock proteins (HSPs) are capable
of integrating both innate and adaptive
immune responses, utilized as
immunostimulatory agents for cancer
vaccines.
56. (3) Protein/peptide-based cancer vaccines
2-Immunostimulatory adjuvants for
protein/peptide-based vaccines.
ā¢ HSPs isolated from cancer cells were able to
induce tumor immunity.
ā¢ First autologous HSP vaccine , OncophageĀ®
approved in Russia as adjuvant in the
treatment RCC.
ā¢ Over coming technical difficulties (tumor
specimen requirement, time-consuming
preparation, ā¦ā¦) formulation of recombinant
HSP vaccines.
57.
58.
59.
60. (4) Genetic vaccines
ā¢ Utilizing viral or plasmid DNA vectors carrying
the expression cassettes to deliver antigen or
antigen fragments in vivo.
ā¢ They transfect somatic cells (myocytes,
keratinocyte) or DCs that infiltrate muscle or
skin as a part of the inflammatory response to
vaccination.
ā¢ Cross-priming or direct antigen presentation.
61.
62. (4) Genetic vaccines
ā¢ Advantage:
ā Easy delivery of multiple antigens in one
immunization.
ā Activation of various arms of the immunity.
ā¢ Types of genetic vaccines:
ā DNA vaccines.
ā RNA vaccines.
ā Viral-based vaccines.
63. (4) Genetic vaccines
1- DNA Vaccines
ā¢ DNA vaccines are bacterial plasmids (vector).
ā¢ Function as shuttle system to deliver and express
tumor antigens.
ā¢ For generation of targeted humoral and cellular
immunity.
ā¢ The backbone of bacterial DNA acts as PAMPs to
stimulate activation of immune cells through
ā TLRs or
ā other innate pattern recognition molecules (PRR).
64. (4) Genetic vaccines
1- DNA Vaccines
ā¢ Incorporate multiple genes ā modulate
intracellular routing and modification of
antigens.
ā eg. Addition of a leader sequence to target
antigens to the endoplasmic reticulum induce:
ā¢ Humoral response.
ā¢ Generation of CD8+ T cell response.
65. (4) Genetic vaccines
1- DNA Vaccines
ā¢ Combined with costimmunaltory agents to
optimize antibody response (eg. TLRs agonist):
ā eg. : DNA cancer vaccine targeting HER2/Neu or
CEA used with TLR9 agonist.
ā¢ ļ” Antibody titers.
ā¢ ļ” ADCC activity.
ā Improvement control of:
ā¢ HER2- positive mammary carcinoma.
ā¢ CEA- positive colon carcinoma.
66. (4) Genetic vaccines
1- DNA Vaccines
ā¢ Fusion of the TAAs (poor immunogenicity) and
non-self antigens or molecules (virus coat, modified
fragment C of tetanus toxin,..)
ā ā T helper signal to CTLs
ā ļØ enhanced cross-presentation of TAAs and
antitumor immunity.
67. (4) Genetic vaccines
1- DNA Vaccines
ā¢ DNA vaccine for vascular endothelial growth
factor receptor 2 :
ā CTL-mediated killing of endothelial cells
ā Therapeutic efficacy against:
ā¢ Melanoma
ā¢ Colon carcinoma
ā¢ Lung carcinoma
68. (4) Genetic vaccines
1- DNA Vaccines
ā¢ DNA vaccine (oral) encoding human endothelial
marker 8:
ā ā Suppress angiogenesis.
ā¢ DNA vaccine encoding HPV E7 fused with
calreticulin:
ā ā Strong CD8+ T cell response.
ā ļØ Immune mediated attack of both cancer cells and
endothelial cells.
ā¢ DNA vaccine targeting angiostatin receptor :
ā ā Immune mediated blockade of angiogenesis.
ā ļØ Tumor inhibition.
69. (4) Genetic vaccines
2- RNA Vaccines
ā¢ mRNA from autologous tumor tissues can be
used to induce CTL response.
ā¢ Total RNA vaccine generate immune response
against various tumor antigens.
ā¢ Due to rapid degradation and clearance :
ā Less side effects and autoimmune diseases than DNA
vaccines.
ā Carried out with stabilizing agents or adjuvants (eg.
liposomes).
ā Integrating replicase polyprotein (self replication).
ā Using beta-globin UTR ā stabilization ā enhanced
antigen-specific immune response.
70. (4) Genetic vaccines
3- Viral Vaccines
ā¢ What is the rationale for using viruses as
immunization vehicles ?
ā Based on the phenomenon that viral infection often
result in the presentation of MHC class I/II restricted,
virus-specific peptides on infected cells.
ā¢ The viral vector:
ā Engineered to encode TAAs or TAAs combined with
immunomodulating molecules.
ā Low disease-causing potential.
ā Low intrinsic immunogenicity.
71.
72. (4) Genetic vaccines
3- Viral Vaccines
ā¢ Vaccinia virus (poxviridae family) most
extensively evaluated viral-based vectors in
cancer vaccine trials due to;
ā Ability to accommodate large or several transgene
inserts.
ā Replication and transcription are restricted to the
cytoplasm (minimizes risk to the host of insertional
mutagenesis).
ā Induction of local inflammatory response by the host
TLRs.
ā Enhance immune response reactive with inserted
TAAs.
73. (4) Genetic vaccines
3- Viral Vaccines
ā¢ PROSTVACĀ® consists of:
1. Replication-comptent vaccinia priming vector.
2. Replication-incomptent fowlpox-boosting vector.
3. Each vector contains transgenes for PSA and
three costimulatory molecules (CD80, CD54 and
DC58).
74.
75.
76.
77.
78. (4) Genetic vaccines
3- Viral Vaccines
ā¢ TROVAXĀ® is a modified vaccinia strain Ankara
(MVA) vector-based cancer vaccine targeting
renal cell carcinoma antigen 5T4.
ā¢ Another MVA vector-based vaccine consists of
expression cassettes encoding MUC1 antigen
and IL-2.
79.
80. (4) Genetic vaccines
3- Viral Vaccines
ā¢ Recombinant adenovirus system:
1. Easy to engineer and propagate to high yields.
2. Transducing both dividing and non-dividing cells
for high expression of transgenes.
3. Adenovirus vectors expressing various TAAs(PSA,
HER2/Neu) are currently being tested for their
clinical efficacy.
4. Newer less immunogenic variants of
adenoviruses and local delivery of adenovirus-
based vaccines
81. (4) Genetic vaccines
3- Viral Vaccines
ā¢ Herpes simplex virus type 1 (HSV-1):
ā Enveloped dsDNA virus
ā Ability to infect a wide variety of cell types.
ā Ability to incorporate singl or multiple transgenes.
ā¢ ONCOVEX GM-CSFĀ®
ā An oncolytic HSV-1 encoding GM-CSF.
ā Direct injected into accessible melanoma lesions
ā Direct oncolytic activity in injected tumors.
ā Secondary immune-mediated antitumor effect.
82. (4) Genetic vaccines
3- Viral Vaccines
ā¢ Like viral vectors, bacteria and yeast have shown
utility as vaccine vehicles in preclinical studies.
ā¢ Modified for immunizing cancer patients.
ā¢ Attenuated recombinant Listeria monocytogenes
induce innate and adaptive antitumor response.
ā¢ Saccharomyces cerevisiae inherently
nonpathogenic and can be easily engineered and
propagated for preparation of a TAA-targeted
vaccine.
83. Reference
ā¢ Chunqing Guo, Masoud H. Manjili, John R.
Subjeck, Devanand Sarkar, Paul B.Fisher, and
Xiang-Yang Wang. Therapeutic Cancer
Vaccines: Past, Present and Future. Adv
Cancer Res. 2013 ; 119: 421ā475.
Editor's Notes
Therapeutic vaccines represent a viable option for active immunotherapy of cancers that aim to treat late stage disease by using a patient's own immune system. The promising results from clinical trials recently led to the approval of the first therapeutic cancer vaccine by the U.S. Food and Drug Administration.
This major breakthrough not only provides a new treatment modality for cancer management, but also paves the way for rationally designing and optimizing future vaccines with improved anticancer efficacy. Numerous vaccine strategies are currently being evaluated both pre-clinically and clinically.
In 1891, Dr. William Coley
Coley toxin = in activated Streptococcus pyogens and Serratia marcescens
The idea came from the observation of spontaneous remission of sarcomas in rare-cancer patients who had developed erysipelas.
Cancer immunotherapy: Coley's Toxin therapy diagram showing how primary tumor in metastatic cancer is injected with Mixed Bacterial Vaccine (MBV) and the percentage chance of durable remission when a patient suffers from inoperable or end-stage colon cancer (CRC) or terminal kidney / real cancer.
Intravesical therapy = put drug into the bladder through a catheter.
BCG has been one of the most successful immunotherapies. BCG vaccine has been the "standard of care for patients with bladder cancer (NMIBC)" since 1977. By 2014 there were more than eight different considered biosimilar agents or strains used for the treatment of nonāmuscle-invasive bladder cancer (NMIBC).
BCG is used in the treatment of superficial forms of bladder cancer. Since the late 1970s, evidence has become available that instillation of BCG into the bladder (through a catheter) is an effective form of immunotherapy in this disease. While the mechanism is unclear, it appears a local immune reaction is mounted against the tumor. Immunotherapy with BCG prevents recurrence in up to 67% of cases of superficial bladder cancer.
BCG has been evaluated in a number of studies as a therapy for colorectal cancer. The US biotech company Vaccinogen is evaluating BCG as an adjuvant to autologous tumour cells used as a cancer vaccine in stage II colon cancer.
BCG has been one of the most successful immunotherapies. BCG vaccine has been the "standard of care for patients with bladder cancer (NMIBC)" since 1977. By 2014 there were more than eight different considered biosimilar agents or strains used for the treatment of nonāmuscle-invasive bladder cancer (NMIBC).
A number of cancer vaccines use BCG as an additive to provide an initial stimulation of the person's immune systems.
BCG is used in the treatment of superficial forms of bladder cancer. Since the late 1970s, evidence has become available that instillation of BCG into the bladder is an effective form of immunotherapy in this disease. While the mechanism is unclear, it appears a local immune reaction is mounted against the tumor. Immunotherapy with BCG prevents recurrence in up to 67% of cases of superficial bladder cancer.
BCG has been evaluated in a number of studies as a therapy for colorectal cancer. The US biotech company Vaccinogen is evaluating BCG as an adjuvant to autologous tumour cells used as a cancer vaccine in stage II colon cancer.
Proposed mechanism of GVAX-PCa action:
Irradiated allogeneic LNCaP and PC-3 tumor cells secrete recombinant GM-CSF, which chemotactically attract immature DCs (1a), inducing DC maturation (1b).
Irradiated tumor cells produce apoptotic bodies (2a) that are taken up by DCs (2b)ācontributing to DC maturation (1b)āand B cells (2b').
Mature DCs activate CD4+ T lymphocytes (1c) and CD8+ T lymphocytes (1c'). Activated CD4+ T lymphocytes further stimulate B-lymphocyte activation (1d) and provide IL-2 for CD8+ T lymphocytes (1d').
B lymphocytes produce TAA-specific antibodies to cell-surface proteins that result in antibody-dependent cell-mediated cytotoxicity or complement-mediated tumor cell death (1e).
Activated CD8+ T lymphocytes then kill tumor cells via recognition of MHC class I molecules in association with TAA epitopes (1e').
CTLA-4 and PD-1/PD-L1 in the immune synapse.
MHC: major histocompatibility complex;
TCR: T cell receptor;
CD: cluster of differentiation;
B7.1 and B7.2 proteins;
CTLA4: cytotoxic T lymphocyte associated antigen 4;
PD1: programmed cell death protein 1;
PD-L1: programmed death-ligand 1;
PD-L2: programmed death-ligand 2.
Cancer vaccines work by providing a target antigen or antigens to a specialized cell known as the dendritic cell (DC). These cells reside at the site of antigen injection (usually intradermal), where they take up and process antigen. Immunostimulatory molecules in the vaccine preparation (adjuvants) activate DCs, which respond by upregulating the molecules they need to interact with (T cells), and migrating to a lymph node. Once in a lymph node, activated DCs present antigen to T cells; if the T cell recognizes its cognate antigen in the proper context, it is then activated. Upon activation, CD4+ T cells produce cytokines that help CD8 T cells to fully mature. Upon full maturation, CD8+ T cells in turn proliferate and then leave the lymph node to traffic widely throughout the body. When an activated T cell senses a cell bearing its target antigen (tumour antigen) in the periphery, it can then lyse that cell, potentially mediating an antitumour response.
signal 1 is the antigen-specific signal that is mediated through T-cell receptor (TCR) triggering by MHC class-II-associated peptides processed from pathogens after internalization through specialized pattern recognition receptors (PRRs).
Signal 2 is the co-stimulatory signal, mainly mediated by triggering of CD28 by CD80 and CD86 that are expressed by dendritic cells (DCs) after ligation of PRRs, such as Toll-like receptors (TLRs) that are specialized to sense infection through recognition of pathogen-associated molecular patterns (PAMPs) or inflammatory tissue factors (TFs).
Signal 3 is the polarizing signal that is mediated by various soluble or membrane-bound factors, such as interleukin-12 (IL-12) and CC-chemokine ligand 2 (CCL2), that promote the development of TH1 or TH2 cells, respectively. The nature of signal 3 depends on the activation of particular PRRs by PAMPs or TFs. Type 1 and type 2 PAMPs and TFs can be defined as those that selectively prime DCs for the production of high levels of TH1-cell-polarizing or TH2-cell-polarizing factors. Whereas, the profile of T-cell-polarizing factors is primed by recognition of PAMPs, optimal expression of this profile often requires feedback stimulation by CD40 ligand (CD40L) expressed by T cells after activation by signals 1 and 2. IFN-Ī³, interferon-Ī³; TNF-Ī², tumour-necrosis factor-Ī².
Mechanism of action of sipuleucel-T, a prostate cancer vaccine
Autologous DCs are isolated from a patientās blood and cultured with a fusion protein consisting of the prostate cancer specific antigen PAP and the APC-activating cytokine GM-CSF (PAP/GM-CSF).
DCs take up and process these antigens, after which they are reinfused into the patient in order to stimulate a T-cell response against PAP expressed on tumor cells in the prostate.
Abbreviations:
APC, antigen-presenting cell; DCs, dendritic cells; GM-CSF, granulocyte-macrophage colony-stimulating factor; PAP, prostatic acid phosphatase.
[Adapted from G. Di Lorenzo, C. Buonerba, and Philip W. Kantoff , 2011 September, Immunotherapy for the treatment of prostate cancer, Nature Reviews Clinical Oncology 8:551ā561.]
Proposed mechanism of sipuleucel-T action.
Infused APCs matured in vitro with GM-CSF fusion protein (1) travel to the spleen, where they present PAP epitopes in association with MHC class I/II molecules (dotted arrows). Sipuleucel-T APCs activate CD4+ T lymphocytes (2), which then provide IL-2 (3b) to PAP-specific CD8+ T lymphocytes that interact with sipuleucel-T APCs (3a). These T lymphocytes then mediate programmed cell death of tumour cells (4).
Key points to improve DC vaccination in cancer patients.
Abbreviations:
CTL, cytotoxic T lymphocyte;
DCs, dendritic cells;
TA, tumor antigen;
LNs, lymph nodes;
Treg, regulatory T cell;
MDSC, myeloid-derived suppressor cell.
Download
Ubiquitin is a small regulatory protein found in most tissues of eukaryotic organisms
Ubiquitination = the kiss of death process ,
A protein is inactivated by attaching ubiquitin to it.
Uubiquitin is a small molecule. It acts as a tag that signals the protein-transport machinery to ferry the protein to the proteosome for degradation
Although known for many years as a nuclear factor (NF)-ĪŗB inhibitory and antiapoptotic signaling protein, A20 has recently attracted much attention because of its ubiquitin-regulatory activities and qualification by genome-wide association studies (GWASs) as a susceptibility gene for inflammatory disease.
Here, we review new findings that have shed light on the molecular and biochemical mechanisms by which A20 regulates inflammatory signaling cascades, and discuss recent experimental evidence characterizing A20 as a crucial gatekeeper preserving tissue homeostasis.
SRA= scavenger receptor A = CD204
Absence of scavenger receptor A promotes dendritic cell-mediated cross-presentation of cell-associated antigen and antitumor immune response
While activating molecules expressed in DCs are involved in a pro-inflammatory or antitumor T cell response, certain suppressive molecules contribute to T- cell tolerance or suppression
Engineering strategies to improve efficacy of DC vaccination:
Strategies used to improve function of ex vivo-engineered DCs are
Loading of tumor antigens in the form of mRNA or a viral vector encoding TAA/neo-antigens or in the form of synthetic TAA/neoantigenic peptides.
Expression of positive regulators of DC function such as T-cell co-stimulatory molecules (CD40L, CD70, OX40L, 4-1BBL), T-cell-stimulating cytokines/chemokines (IL-12p70, TNF-Ī±, CCL21, CXCL10) and DC-activating receptors (TLR-4).
Silencing of negative regulators of DC function such as immune suppressive cytokines/cytokine receptors (IL-10/IL-10R, TGF-Ī²R), checkpoint inhibitor ligands (PD-L1, PD-L2) and other suppressive molecules such as IDO.
Alternatively, DCs can be targeted in vivo by administration of oncolytic viruses encoding DC/T-cell-stimulating cytokines and co-stimulatory molecules (Il-12p70, GM-CSF, CD40L), administration of DC-targeting antibodies tagged with TAA, administration of TLR-activating ligands (CpG, polyI:C) or administration of agonistic DC-activating antibodies (Ī±-CD40 antibody).
SR scavenger receptor
Administration
Resulting in
In therapeutic setting, active immunization with HER2/Neu DNA vaccine synergized with anti-HER2/Neu monoclonal antibodies for enhanced inhibition of established mouse breast tumors.
Achieving an effective and durable CTL response remains the ultimate goal of cancer vaccines.
Generation of CD4+ T cell help via Class II MHC-dependent pathway is important for amplification CD8+ T cell responses and maintainence of memory during DNA vaccination.
DNA vaccines have also been tested for immune targeting of stable, proliferarting endothelialcells in the tumor vasculature.
Calreticulin : multifuctional protein that acts as a major (Ca2+)-binding (storage ) protein in the lumen of the endoplasmic reticulum.
Tumor lysis oncolytic virus
ProStvaC mechanism of action. PSA: Prostate-specific antigen; TAA: Tumor-associated antigen; TRICOM: Triad of T-cell costimulatory molecules. Figure was provided by Bavarian Nordic, Inc., Mountain View, CA, USA.
Proposed mechanisms of PROSTVACĀ® VF action.
In pathway 1, the vaccinia virus infects immature or mature DCs, which travel to draining lymph nodes and express co-stimulatory proteins and MHC class I/PSA epitopes (1a). These cells then trigger the activation and proliferation of PSA-specific CD8+ T lymphocytes (1b), which circulate to tumour sites and kill tumour cells via PCD (1c).
In pathway 2, the vaccinia virus infects somatic cells (2a), which then directly activate PSA-specific CTLs (2b) and NK cells (2b'). These cells then induce PCD of somatic cells (2c and 2c'), which are taken up by DCs that are activated by viral components to mature and cross-present PSA (2d). These mature DCs further stimulate PSA-specific CTL activation (2e), causing PCD of tumour cells (2f).
Abbreviations: CTL, cytotoxic T lymphocyte; DC, dendritic cell; NK cell, natural killer cell; PCD, programmed cell death.